Cargando…

Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials

SIMPLE SUMMARY: The mortality of hepatocellular carcinoma (HCC) is quickly increasing worldwide. Immunotherapy enables the immune defense of the organism to target liver cancer cells. Recent technologies enable engineering of immune cells, and notably T lymphocytes, to make them more efficient again...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rochigneux, Philippe, Chanez, Brice, De Rauglaudre, Bernadette, Mitry, Emmanuel, Chabannon, Christian, Gilabert, Marine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828372/ https://www.ncbi.nlm.nih.gov/pubmed/33450845 http://dx.doi.org/10.3390/cancers13020271

Ejemplares similares

Assessment of biological effect of nab-paclitaxel combined with gemcitabine, using contrast enhanced ultrasonography and elastography, in advanced pancreatic ductal carcinoma: A single-center pilot study
por: Dahel, Yanis, et al.
Publicado: (2023)

Impact of fiducial markers placement on the delineation of target volumes in radiation therapy for oesophageal cancer: FIDUCOR study
por: Rochigneux, Philippe, et al.
Publicado: (2022)

Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review
por: Rochigneux, Philippe, et al.
Publicado: (2020)

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
por: Faure, Marjorie, et al.
Publicado: (2018)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma
por: Billon, Emilien, et al.
Publicado: (2021)

Is the Rationale of Anatomical Liver Resection for Hepatocellular Carcinoma Universally Adoptable? A Hypothesis-Driven Review
por: Lin, Young-Jen, et al.
Publicado: (2021)

Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study
por: Chanez, Brice, et al.
Publicado: (2021)

Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report
por: Leblanc, Julie, et al.
Publicado: (2021)

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
por: Gilabert, Marine, et al.
Publicado: (2018)

Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia
por: Thuret, Isabelle, et al.
Publicado: (2022)

Current options and future possibilities for the systemic treatment of hepatocellular carcinoma
por: Raoul, Jean-Luc, et al.
Publicado: (2019)

PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
por: Birnbaum, David Jeremie, et al.
Publicado: (2023)

How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma
por: Raoul, Jean-Luc, et al.
Publicado: (2016)

Rationales and arguments behind the adoption of self-selection of nonprescription medicines in Denmark
por: Jacobsen, Solveig Nordahl, et al.
Publicado: (2020)

TranslatiOnal Registry for CardiomyopatHies (TORCH) – rationale and first results
por: Seyler, Claudia, et al.
Publicado: (2017)

The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results
por: Thiel, Sandra, et al.
Publicado: (2021)

A Biological Rationale for Musical Scales
por: Gill, Kamraan Z., et al.
Publicado: (2009)

Hepatocellular Carcinoma in a Noncirrhotic Liver after Long-Term Use of Danazol for Hereditary Angioedema
por: Rahal, Soraya, et al.
Publicado: (2014)

The Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) Core Measures Project: Rationale and Approach
por: MacLean, Paul S., et al.
Publicado: (2018)

Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
por: Tai, David, et al.
Publicado: (2019)

The promise of adoptive cellular immunotherapies in hepatocellular carcinoma
por: Hendrickson, Peter G., et al.
Publicado: (2019)

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
por: Planes-Laine, Gabrielle, et al.
Publicado: (2019)

First phase of installation of FASER in the LHC tunnel
por: Brice, Maximilien
Publicado: (2020)

Radiation Oncology—Rationale, Technique, Results
por: Bleehen, N. M.
Publicado: (1980)

Patient-Treatment Matching: Rationale and Results
por: Mattson, Margaret E.
Publicado: (1994)

Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy
por: Wlosik, J., et al.
Publicado: (2022)

OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients
por: Vachenc, Sébastien, et al.
Publicado: (2022)

The First National Survey of Indigenous People’s Health and Nutrition in Brazil: rationale, methodology, and overview of results
por: Coimbra, Carlos EA, et al.
Publicado: (2013)

Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records
por: Beaufils, Mathilde, et al.
Publicado: (2023)

The transrectus sheath preperitoneal mesh repair for inguinal hernia: technique, rationale, and results of the first 50 cases
por: Koning, G. G., et al.
Publicado: (2011)

Rationale of using different biological therapies in rheumatoid arthritis
por: Geyer, Matthias, et al.
Publicado: (2010)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

Biological and Clinical Rationale for Androgen Priming in Ovarian Stimulation
por: Løssl, Kristine, et al.
Publicado: (2020)

Immune biological rationales for the design of combined radio- and immunotherapies
por: Hader, Michael, et al.
Publicado: (2020)

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
por: Ren, Zhenggang, et al.
Publicado: (2022)

General Surgery: Requirements, Rationale, and Robust Results
por: Jain, Sunil, et al.
Publicado: (2022)

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives
por: Roccuzzo, Gabriele, et al.
Publicado: (2021)

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
por: van den Heuvel, Michel M, et al.
Publicado: (2015)

Adipose-Derived Stem Cells in the Treatment of Perianal Fistulas in Crohn’s Disease: Rationale, Clinical Results and Perspectives
por: Buscail, Etienne, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vp2td17hndepmkm5iur8m69lno